Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Dyne Therapeutics, Inc. (DYN) had Return on Tangible Equity of -15.62% for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-108.04M |
|
-- |
|
-- |
|
$113.89M |
|
$-113.89M |
|
$5.85M |
|
$-108.04M |
|
$-108.04M |
|
$-108.04M |
|
$-108.04M |
|
$-108.04M |
|
$-108.04M |
|
$-113.89M |
|
$-113.74M |
|
141.81M |
|
141.81M |
|
$-0.76 |
|
$-0.76 |
|
| Balance Sheet Financials | |
$806.26M |
|
$23.97M |
|
$60.80M |
|
$867.06M |
|
$59.85M |
|
$99.15M |
|
$115.43M |
|
$175.28M |
|
$691.78M |
|
$691.78M |
|
$691.78M |
|
142.61M |
|
| Cash Flow Statement Financials | |
$-291.38M |
|
$-29.73M |
|
$459.34M |
|
$437.39M |
|
$575.62M |
|
$138.23M |
|
$34.62M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
13.47 |
|
-- |
|
-- |
|
0.13 |
|
0.14 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-292.81M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-15.62% |
|
|
Return on Tangible Equity |
-15.62% |
-12.46% |
|
-13.66% |
|
$4.85 |
|
$-2.06 |
|
$-2.05 |
|